Tempus AI (NASDAQ:TEM) Stock Rating Lowered by Wall Street Zen

Tempus AI (NASDAQ:TEM) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Several other analysts have also recently commented on the stock. BTIG Research decreased their price objective on shares of Tempus AI from $105.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Tempus AI in a report on Thursday, January 22nd. Canaccord Genuity Group decreased their target price on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, December 22nd. Mizuho initiated coverage on Tempus AI in a research report on Thursday, February 19th. They set an “outperform” rating and a $100.00 price target on the stock. Finally, HC Wainwright reduced their price objective on Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Eight equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Tempus AI has an average rating of “Moderate Buy” and a consensus price target of $79.31.

Tempus AI Trading Down 3.9%

Tempus AI stock opened at $53.25 on Friday. The stock has a 50-day moving average price of $61.34 and a 200 day moving average price of $73.28. The company has a market capitalization of $9.47 billion, a price-to-earnings ratio of -37.77 and a beta of 5.22. Tempus AI has a 52 week low of $36.22 and a 52 week high of $104.32. The company has a quick ratio of 3.12, a current ratio of 3.13 and a debt-to-equity ratio of 2.52.

Insider Activity at Tempus AI

In other news, CAO Ryan M. Bartolucci sold 2,902 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $171,363.10. Following the sale, the chief accounting officer directly owned 41,159 shares of the company’s stock, valued at $2,430,438.95. This represents a 6.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO James William Rogers sold 10,084 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $595,460.20. Following the sale, the chief financial officer owned 101,166 shares in the company, valued at $5,973,852.30. This trade represents a 9.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 596,035 shares of company stock valued at $37,505,125 in the last quarter. 26.27% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds have recently bought and sold shares of the business. Virtu Financial LLC grew its holdings in Tempus AI by 384.6% in the fourth quarter. Virtu Financial LLC now owns 54,797 shares of the company’s stock valued at $3,236,000 after purchasing an additional 43,490 shares during the period. Invesco Ltd. lifted its position in shares of Tempus AI by 21.5% during the 4th quarter. Invesco Ltd. now owns 371,674 shares of the company’s stock valued at $21,947,000 after buying an additional 65,836 shares in the last quarter. Vident Advisory LLC lifted its position in shares of Tempus AI by 5.3% during the 4th quarter. Vident Advisory LLC now owns 10,376 shares of the company’s stock valued at $613,000 after buying an additional 522 shares in the last quarter. Oracle Investment Management Inc. acquired a new stake in Tempus AI in the 4th quarter valued at $384,000. Finally, EP Wealth Advisors LLC purchased a new stake in Tempus AI in the 4th quarter worth $553,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Beat-and-raise fundamentals — Tempus reported robust Q4 and full‑year 2025 results (strong revenue growth, narrower net loss, positive adjusted EBITDA progression) and issued 2026 guidance that targets revenue growth and a first full‑year adjusted EBITDA inflection, supporting a fundamental recovery case. Why Tempus AI (TEM) Is Down 7.5% After 2025 Results
• Positive Sentiment: Product & commercial catalysts — Launch of an HRD‑RNA oncology algorithm and a partnership with Median Technologies to expand lung cancer screening distribution broaden Tempus’s diagnostic pipeline and addressable market if adoption scales. Tempus AI Deepens Precision Oncology Role With New HRD And Lung Tools
• Positive Sentiment: Institutional support and rebound narrative — Several outlets highlight heavy institutional buying, improving unit economics and analyst upside scenarios, which could limit downside and set up a technical rebound if execution continues. Tempus AI Sold Off After a Beat—But the Rebound Case Is Building
• Neutral Sentiment: Investor event calendar — Management will present at the Morgan Stanley TMT conference (March 3); the fireside chat could provide additional color but is not a guaranteed catalyst. Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference
• Neutral Sentiment: Valuation updates — Some fair‑value and price‑target revisions trimmed upside modestly; analysts still show a range of bullish and cautious views, leaving the story sensitive to near‑term execution. How The Tempus AI (TEM) Investment Story Is Evolving With New Data And Valuation Views
• Negative Sentiment: Analyst downgrades and price‑target cuts — Recent analyst actions (including a notable downgrade reported 2/27 and several target cuts in the prior 24 hours) have intensified selling pressure and weakened sentiment despite the beat. Tempus AI (NASDAQ:TEM) Shares Down 7.4% After Analyst Downgrade
• Negative Sentiment: ESOP shelf registration and dilution risk — Tempus filed a US$343.38M ESOP‑related shelf registration; potential future share issuance tied to employee plans can pressure the stock if investors fear dilution. Why Tempus AI (TEM) Is Down 7.5% After 2025 Results
• Negative Sentiment: Execution, debt and market risk — High leverage, a volatile post‑IPO trading history, elevated beta and lingering execution/valuation concerns make the stock susceptible to outsized moves on negative headlines. Is It Time To Reassess Tempus AI (TEM) After Recent Share Price Weakness?

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.